LCM
EWTX icon

Laurion Capital Management’s Edgewise Therapeutics EWTX Stock Holding History

Laurion Capital Management’s Portfolio EWTX Stock Details EWTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-57,213
Closed -$455K – 527
2022
Q2 		$455K Sell
57,213
-83,759
-59% -$633K 0.01% 343
2022
Q1 		$1.37M Buy
+140,972
New +$1.81M 0.02% 236

Other funds holding EWTX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Laurion Capital Management's EWTX Position: Q3 2022 in Review

Laurion Capital Management sold out of Edgewise Therapeutics (EWTX) in Q3 2022, closing a stake of 57,213 shares — an estimated $455K sold.

Laurion Capital Management first reported a position in EWTX in Q1 2022 and held it in 2 quarters. The position peaked at $1.37M in Q1 2022. 94 funds tracked by Wall St. Rank hold EWTX as of Q3 2022.

  • Laurion Capital Management reported no remaining Edgewise Therapeutics position as of Q3 2022 after selling out during the quarter.
  • Laurion Capital Management sold 57,213 Edgewise Therapeutics shares in Q3 2022, an estimated $455K.
  • Laurion Capital Management first reported a position in Edgewise Therapeutics in Q1 2022 and held it in 2 quarters.
  • Laurion Capital Management's Edgewise Therapeutics position peaked at $1.37M in Q1 2022.
  • 94 funds tracked by Wall St. Rank held Edgewise Therapeutics as of Q3 2022.

Based on Laurion Capital Management's 13F filing for Q3 2022, filed 14 Nov 2022.